RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence

According to DataM Intelligence, "The RNA-Based Therapies Market Size, valued at USD 90.56 billion in 2024, is projected to ...

Tempus AI Shares Up After FDA Clearance for In Vitro Diagnostic Device

Tempus AI Inc. shares rose after it said it received 510 (k) clearance from the Food and Drug Administration for its RNA-based in vitro diagnostic device. Its stock recently rose 5.2% to $92.85 in ...
Precision Medicine Online

FDA Mulling Existing Data Types Sponsors May Leverage to Speed Cell, Gene Therapies to Market

The agency held a meeting to gather drugmakers' perspectives as it considers a draft guidance on how previously generated ...
Investing.com Philippines

Tempus AI stock rises after FDA clearance for RNA sequencing device

Investing.com -- Tempus AI, Inc. (NASDAQ:TEM) stock rose 5% on Monday after the company announced it received 510 (k) clearance from the U.S. Food and Drug Administration for its RNA-based Tempus xR ...
TMCnet

Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510 (k) clearance from the U.S. Food and ...